Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis.
Vincent T JanmaatSophie H van OlphenKatharina E BiermannLeendert H J LooijengaMarco B BrunoManon C W SpaanderPublished in: PloS one (2017)
Use of p53 IHC staining may improve risk stratification in BE surveillance. Aberrant p53 expression in BE patients appeared to be associated with a significantly increased risk of neoplastic progression for both non-dysplastic and LGD BE patients.